In vivo pretreatment with PGG-Glucan fails to alter cytokine mRNA expression of equine peripheral blood mononuclear cells exposed to endotoxin ex vivo

Veterinary Therapeutics

Volumn 6, Issue 1, 2005, Pages 67-76

  Sykes, Benjamin W ^a   Furr, Martin ^b   Giguère, Steeve ^c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MARION DUPONT SCOTT EQUINE MEDICAL CENTER   (United States)

^c University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAFECTIN; CYTOKINE; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; BETA GLUCAN; DIAGNOSTIC AGENT; POLY 1 6 GLUCOPYRANOSYL 1 3 GLUCOPYRANOSE GLUCAN; POLY-1-6-GLUCOPYRANOSYL-1-3-GLUCOPYRANOSE GLUCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; HORSE; IN VIVO STUDY; INCUBATION TIME; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; ANIMAL; ANIMAL DISEASE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; GENETICS; METABOLISM; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL;

EQUIDAE; EQUUS CABALLUS;

ANIMALS; BETA-GLUCANS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; ENDOTOXINS; HORSES; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 20344397408     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Sykes B, Furr M: Equine endotoxemia - A state of the art review of therapy. Aust Vet J 83(1):45-50, 2005.
2. Grulke S, Olle E, Detilleux J: Determination of a gravity and shock score for prognosis in equine surgical colic. J Vet Med 48:465-473, 2001.
3. Thoefner MB, Ersboll A, Jensen AL, Hesselholt M: Factor analysis of the interrelationship between clinical variables in horses with colic. Prev Vet Med 48(3):201-214, 2001.
4. Furr MO, Lessard P, White N: Development of a colic severity score for predicting the outcome of equine colic. Vet Surg 24(2):97-101, 1995.
5. Parry BW, Anderson G, Gay CC: Prognosis in equine colic: A study of individual variables used in case assessment. Equine Vet J 15(4):337-344, 1983.
6. Durando MM, MacKay R, Linda S, Skelley LA: Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 55(7):921-927, 1994.
7. Garner HE, Sprouse R, Lager K: Cross protection of ponies from sublethal Escherichia coli endotoxemia by Salmonella typhimurium antiserum. Equine Pract 10(4):10-16, 1988.
8. Morris DD, Whitlock R, Corbeil LB: Endotoxemia in horses: Protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 47(3):544-550, 1986.
9. Morris DD, Whitlock R: Therapy of suspected septicemia in neonatal foals using plasma containing antibodies to core lipopolysaccharide (LPS). J Vet Intern Med 1(4):175-182, 1987.
10. Spier SJ, Lavoie J, Cullor JS, et al: Protection against clinical endotoxemia in horses by using plasma containing antibody to an Rc mutant E. coli (J5). Circ Shock 28(2):235-248, 1989.
11. MacKay RJ, Clark C, Logdberg L, Lake P: Effect of a conjugate of polymyxin B-dextran 70 in horses with experimentally induced endotoxemia. Am J Vet Res 60(1):68-75, 1999.
12. Parviainen AK, Barton M, Norton NN: Evaluation of polymyxin B in an ex vivo model of endotoxemia in horses. Am J Vet Res 62(1):72-76, 2001.
13. Barton MH, Moore J: Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 44(4):216-220, 1994.
14. Barton MH, Moore J, Norton NN: Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 58(11):1300-1307, 1997.
15. Baskett A, Barton M, Norton N, et al: Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 58(11):1291-1299, 1997.
16. Vincent JL, De Backer D: Pathophysiology of septic shock. Adv Sepsis 1(3):87-92, 2001.
17. Heumann D, Roger T: Initial responses to endotoxins and gram negative bacteria. Clin Chem Acta 323(1-2): 59-72, 2002.
18. Rongione AJ, Kusske A, Kwan K, et al: Interleukin-10 protects against lethality of intra-abdominal infection and sepsis. J Gastrointest Surg 4(1):70-76, 2000.
19. Billiau A, Heremans H, Vermeire K, Matthys P: Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci 856:22-32, 1998.
20. Doherty GM, Lange J, Langstein HN, et al: Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor alpha. J Immunol 149(5):1666-1670, 1992.
21. Liang J, Melican D, Cafro L, et al: Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 20(11):595-614, 1998.
22. Mackin W, Brunke-Reese D, Crotty C, et al: Beta-fectin PGG-glucan potentiates the microcidal activities of human leukocytes measures ex vivo in healthy human volunteers. FASEB J 9:A521, 1995.
23. Kernodle DS, Gates H, Kaiser AB: Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopyranosyl glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother 42(3):545-549, 1998.
24. Tzianabos AO, Cisneros R: Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic resistant bacteria. Ann N Y Acad Sci 797:285-287, 1996.
25. Onderdonk AB, Cisneros R, Hinkston P, Ostroff G: Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3 glucopyranose glucan in vivo. Infect Immunol 60(4):1642-1647, 1992.
26. Babineau TJ, Hackford A, Kenler A, et al: A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high risk surgical patients. Arch Surg 129(11):1204-1210, 1994.
27. Babineau TJ, Marcello P, Swails W, et al: Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high risk surgical patients. Ann Surg 220(5):601-609, 1994.
28. Soltys J, Quinn M: Modulation of endotoxin and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6) branched beta (1,3)-glucan. Infect Immunol 67(1):244-252, 1999.
29. Ahmed A, Furr M, Chickering W, et al: Immunologie studies in a horse with lymphosarcoma. Vet Immunol Immunopathol 38(3-4):229-239, 1993.
30. Barton MH, Collatos C, Moore JN: Endotoxin induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages. Equine Vet J 28(5):382-389, 1996.
31. Garton NJ, Gilleron M, Brando T, et al: A novel lipoarabinomannan from the equine pathogen Rhodococcus equi. Structure and effect on macrophage cytokine production. J Biol Chem 277(35):31722-31733, 2002.
32. Waksull E, Brunke-Reese D, Lindermuth J, et al: PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: Evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology 41(2):89-107, 1999.
33. Standiford TJ, Stricter R, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 155(4):2222-2229, 1995.
34. Yamano S, Scott D, Huang LY, et al: Protection from experimental endotoxemia by a recombinant adeno-associated virus encoding interleukin 10. J Gene Med 3(5):450-457, 2001.